MedTrace Logo

Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult Volunteers

NCT01577849 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2016-11-01

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetic characteristics of DP-R206 (150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) and Vitamin D3 (24,000 IU Vitamin D3 , qd) after oral administration in healthy adult volunteers.

Conditions

  • Healthy

Interventions

DRUG

Vitamin D3

administration of Vitamin D3 24,000 IU

DRUG

DP-R206

administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)

Sponsors & Collaborators

  • Alvogen Korea

    lead INDUSTRY

Principal Investigators

  • Min Gul KIM, MD · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01577849 on ClinicalTrials.gov